IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer announced today the release of an exclusive feature that reduces the power consumption of IBA proton therapy 230 MeV isochronous cyclotron (C230) by >30%. This unique feature helps reduce the overall cost of proton therapy, making it ever more accessible to patients worldwide.

First measurements at the Institut Curie’s Orsay Proton Therapy Center (France) show that the power consumption of the cyclotron has been lowered by an average of 30% over a month’s period.

“This is significant” said Frédéric Genin, Executive Vice President, Product Development Management at IBA “this feature is a great accomplishment. It dramatically reduces the operation costs of proton therapy centers hence making the treatment more affordable and the technology more accessible. It is only a first step as additional energy saving features are being tested to further reduce energy-related costs. ”

Weisheng Duan, Product Manager at IBA added: “This new feature can be retrofitted to all existing systems.. It addresses a major area of concern for our customers as the prices of energy are generally going up. It will help them to significantly reduce their energy bill while making a positive impact on the environment. ”

The IBA Isochronous Cyclotron (C230) enables physicians to deliver the highest quality clinical proton beam that is both highly precise and symmetrical with a very stable energy of 230MeV and a high yield. It benefits from the experience gained over 25 years at 16 operating centers. This new generation has been designed with clinical operations in mind. It offers automatic operations, remote monitoring and predicative maintenance programs. IBA provides its customers the highest uptime in the radiation therapy market to ensure maximum system availability for cancer patient treatment.

Truong Duy